Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for ...
TOKYO, May 22, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous ...
TOKYO, Sept 26, 2022 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have obtained ...
Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft für klinische Spezialpräparate mbH announced that they have obtained manufacturing and marketing approval from the ...
TOKYO, Nov 16, 2022 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have launched the ...
de la polyarthrite rhumatoïde active et sévère chez l'adulte, des formes polyarticulaires de l'arthrite juvénile idiopathique active sévère, en cas de réponse inadéquate aux anti-inflammatoires non ...
METOJECT est indiqué dans le traitement : - de la polyarthrite rhumatoïde active et sévère de l'adulte, - des formes polyarticulaires actives et sévères de l'arthrite idiopathique juvénile en cas de ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results